1. Home
  2. NXGL vs MTNB Comparison

NXGL vs MTNB Comparison

Compare NXGL & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.42

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Logo Matinas Biopharma Holdings Inc.

MTNB

Matinas Biopharma Holdings Inc.

HOLD

Current Price

$0.25

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
MTNB
Founded
1997
2013
Country
United States
United States
Employees
19
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
5.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NXGL
MTNB
Price
$0.42
$0.25
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
330.7K
578.3K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.84
EPS
N/A
N/A
Revenue
N/A
$119,750.00
Revenue This Year
$50.77
N/A
Revenue Next Year
$46.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.26
52 Week High
$2.89
$3.09

Technical Indicators

Market Signals
Indicator
NXGL
MTNB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NXGL
MTNB

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

Share on Social Networks: